Optimizing Early Biomarker Testing to Guide Clinical Decision-Making in Colorectal Cancer Across Latin America
Pfizer Inc. funds educational projects to advance early biomarker testing and guide clinical decision-making in colorectal cancer throughout Latin America.
Funder: Pfizer Inc.
Due Dates: September 10, 2026 (Submission Deadline)
Funding Amounts: $50,000–$100,000 USD (single-country projects); up to $200,000 USD (multi-country); total budget $250,000 USD
Summary: Supports independent education to enhance early biomarker testing and clinical decision-making in colorectal cancer across Latin America.
Key Information: Only organizations (not individuals or practice groups) in Mexico, Brazil, Colombia, Peru, Chile, or Argentina are eligible.
Description
This grant opportunity, offered by Pfizer Inc., aims to advance the understanding and integration of early biomarker testing in colorectal cancer (CRC) care throughout Latin America. The program supports independent educational initiatives that address gaps in clinical implementation, promote evidence-based practices, and foster multidisciplinary collaboration among clinicians and diagnostics experts. The goal is to improve patient outcomes and standardize care by encouraging the adoption of precision oncology principles.
